Thromb Haemost 1992; 67(03): 306-309
DOI: 10.1055/s-0038-1648437
Original Articles
Schattauer GmbH Stuttgart

Double-Blind, Randomized Comparison of Systemic Continuous Infusion of 0.25 Versus 0.50 mg/kg/24 h of Alteplase over 3 to 7 Days for Treatment of Deep Venous Thrombosis in Heparinized Patients: Results of the European Thrombolysis with rt-PA in Venous Thrombosis (ETTT) Trial[*]

H Bounameaux
Geneva, Switzerland; Utrecht, The Netherlands; Bologna, Italy; Paris, France; Huddinge, Sweden; Bern, Switzerland; Lyon, France; La Chaux-de-Fonds, Switzerland; Groningen, The Netherlands; and Leuven, Belgium
,
J D Banga
Geneva, Switzerland; Utrecht, The Netherlands; Bologna, Italy; Paris, France; Huddinge, Sweden; Bern, Switzerland; Lyon, France; La Chaux-de-Fonds, Switzerland; Groningen, The Netherlands; and Leuven, Belgium
,
E Bluhmki
Geneva, Switzerland; Utrecht, The Netherlands; Bologna, Italy; Paris, France; Huddinge, Sweden; Bern, Switzerland; Lyon, France; La Chaux-de-Fonds, Switzerland; Groningen, The Netherlands; and Leuven, Belgium
,
S Coccheri
Geneva, Switzerland; Utrecht, The Netherlands; Bologna, Italy; Paris, France; Huddinge, Sweden; Bern, Switzerland; Lyon, France; La Chaux-de-Fonds, Switzerland; Groningen, The Netherlands; and Leuven, Belgium
,
J N Fiessinger
Geneva, Switzerland; Utrecht, The Netherlands; Bologna, Italy; Paris, France; Huddinge, Sweden; Bern, Switzerland; Lyon, France; La Chaux-de-Fonds, Switzerland; Groningen, The Netherlands; and Leuven, Belgium
,
W Haarmann
Geneva, Switzerland; Utrecht, The Netherlands; Bologna, Italy; Paris, France; Huddinge, Sweden; Bern, Switzerland; Lyon, France; La Chaux-de-Fonds, Switzerland; Groningen, The Netherlands; and Leuven, Belgium
,
D Lockner
Geneva, Switzerland; Utrecht, The Netherlands; Bologna, Italy; Paris, France; Huddinge, Sweden; Bern, Switzerland; Lyon, France; La Chaux-de-Fonds, Switzerland; Groningen, The Netherlands; and Leuven, Belgium
,
F Mahler
Geneva, Switzerland; Utrecht, The Netherlands; Bologna, Italy; Paris, France; Huddinge, Sweden; Bern, Switzerland; Lyon, France; La Chaux-de-Fonds, Switzerland; Groningen, The Netherlands; and Leuven, Belgium
,
J Ninet
Geneva, Switzerland; Utrecht, The Netherlands; Bologna, Italy; Paris, France; Huddinge, Sweden; Bern, Switzerland; Lyon, France; La Chaux-de-Fonds, Switzerland; Groningen, The Netherlands; and Leuven, Belgium
,
P A Schneider
Geneva, Switzerland; Utrecht, The Netherlands; Bologna, Italy; Paris, France; Huddinge, Sweden; Bern, Switzerland; Lyon, France; La Chaux-de-Fonds, Switzerland; Groningen, The Netherlands; and Leuven, Belgium
,
A de Torrente
Geneva, Switzerland; Utrecht, The Netherlands; Bologna, Italy; Paris, France; Huddinge, Sweden; Bern, Switzerland; Lyon, France; La Chaux-de-Fonds, Switzerland; Groningen, The Netherlands; and Leuven, Belgium
,
J van der Meer
Geneva, Switzerland; Utrecht, The Netherlands; Bologna, Italy; Paris, France; Huddinge, Sweden; Bern, Switzerland; Lyon, France; La Chaux-de-Fonds, Switzerland; Groningen, The Netherlands; and Leuven, Belgium
,
and R Verhaeghe
Geneva, Switzerland; Utrecht, The Netherlands; Bologna, Italy; Paris, France; Huddinge, Sweden; Bern, Switzerland; Lyon, France; La Chaux-de-Fonds, Switzerland; Groningen, The Netherlands; and Leuven, Belgium
› Author Affiliations
Further Information

Publication History

Received 02 July 1991

Accepted after revision 13 September 1991

Publication Date:
03 July 2018 (online)

Preview

Summary

Thirty-two patients with acute, proximal-vein thrombosis were treated with heparin and alteplase (0.25 versus 0.5 mg/kg/24 h during 3-7 days) in a randomized, double-blind, multicenter, European (ETTT) trial. The treatment resulted in a decrease of the venographic Marder’s score from 18 (6-25) to 13 (2-24) units (median, range) in Group I (0.25 mg/kg/24 h, n = 15, median decrease 3.0, p = 0.32) and from 17.5 (3-33) to 15.5 (0-27) in Group II (0.5 mg/kg/24 h, n = 16, median decrease 4.0, p = 0.23). Comparison of the sequential venograms could be performed in 14 cases of Group I and in 15 cases in Group II. A minority of patients showed substantial partial recanalization of the initially obstructed veins on the control venogram (one in each treatment group) and most of the control venograms showed

Thus, the results of the ETTT trial show that the used low dosages of alteplase administered intravenously over 3-7 days in heparinized patients cannot be recommended as a treatment for patients with deep venous thrombosis of lower limbs and/or pelvis. Further studies are needed to define a more suitable dosage regimen of alteplase in this indication.

Complete list of the participating centers and investigators at the end of the paper